产品名称
Genistein, Soybean, A cell-permeable, reversible, substrate competitive inhibitor of protein tyrosine kinases, including autophosphorylation of epidermal growth factor receptor kinase (IC50 = 2.6 µM).
Quality Level
description
Merck USA index - 14, 4391
assay
≥95% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
white
solubility
DMSO: 200 mg/mL
shipped in
ambient
storage temp.
−20°C
SMILES string
[o]1c2c([c](c(c1)c3ccc(cc3)O)=O)c(cc(c2)O)O
InChI
1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18H
InChI key
TZBJGXHYKVUXJN-UHFFFAOYSA-N
General description
A cell-permeable, reversible, substrate competitive inhibitor of protein tyrosine kinases, including autophosphorylation of epidermal growth factor receptor kinase (IC50 = 2.6 µM). The inhibition is competitive with respect to ATP and non-competitive with respect to the phosphate acceptor. Inhibits tumor cell proliferation and induces tumor cell differentiation. Inhibits exogenous substrate phosphorylation by EGFR kinase and pp60v-src with similar potencies (IC50 = 20-25 µM). Has only a trivial effect on PKC and PKA (IC50 >350 µM). Produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells. Prevents anti-CD3 monoclonal antibody-induced thymic apoptosis. Also inhibits topoisomerase II activity in vitro. Blocks oxidative DNA damage in vitro.
Biochem/physiol Actions
Primary Target
EGFR kinase
EGFR kinase
Product does not compete with ATP.
Reversible: yes
Target IC50: 2.6 µM against autophosphorylation of epidermal growth factor receptor kinase
Cell permeable: yes
Other Notes
Constantinou, A., and Huberman, E. 1995. Proc. Soc. Exp. Biol. Med. 208, 109.
Wei, H., et al. 1995. Proc. Soc. Exp. Biol. Med. 208, 124.
Wei, H., et al. 1995. Carcinogenesis17, 73.
Kobayashi, S., et al. 1994. J. Biol. Chem.269, 9011.
Migita, K., et al. 1994. J. Immunol.153, 3457.
Spinozzi, F., et al. 1994. Leuk. Res.18, 431.
Dhar, A., et al. 1990. Mol. Pharmacol.37, 519.
Hill, T.D., et al. 1990. Science248, 1660.
Dean, N.M., et al. 1989. Biochem. Biophys. Res. Commun.165, 795.
Akiyama, T., et al. 1987. J. Biol. Chem.262, 5592.
Wei, H., et al. 1995. Proc. Soc. Exp. Biol. Med. 208, 124.
Wei, H., et al. 1995. Carcinogenesis17, 73.
Kobayashi, S., et al. 1994. J. Biol. Chem.269, 9011.
Migita, K., et al. 1994. J. Immunol.153, 3457.
Spinozzi, F., et al. 1994. Leuk. Res.18, 431.
Dhar, A., et al. 1990. Mol. Pharmacol.37, 519.
Hill, T.D., et al. 1990. Science248, 1660.
Dean, N.M., et al. 1989. Biochem. Biophys. Res. Commun.165, 795.
Akiyama, T., et al. 1987. J. Biol. Chem.262, 5592.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
J C Norman et al.
FEBS letters, 484(3), 179-183 (2000-11-18)
Aggregation by immune complexes of receptors specific for the Fc region of IgG results in their internalisation and disposal by trafficking to lysosomes. We show here that internalisation of FcgammaRI by IFN-gamma treated U937 cells following receptor aggregation by cross-linking
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 345834-20MG | 04055977214376 |
| 345834-50MG | 04055977214383 |
